USFDA warning letter on Lupin#39;s Somerset facility cites repeated GMP violations at Lupin#39;s manufacturing network

"Repeated violations at multiple sites demonstrate that your company’s corporate oversight and control over the manufacture of drugs is inadequate," USFDA said in its warning letter addressed to Vinita Gupta, CEO of Lupin.

from Moneycontrol Business News https://ift.tt/3x6aK4p